Business Wire

Lenovo Group: Full Year Financial Results 2020/21

Share

Lenovo Group (HKSE: 992) (PINK SHEETS: LNVGY) today announced record results for the Group for both its fourth quarter and fiscal year, with phenomenal growth across all parts of the business. The results demonstrate the Group’s resilience and ability to achieve balanced, consistent, and sustainable growth as it continues to diversify and transform in line with its 3S (Smart IoT, Smart Infrastructure, Smart Solutions) corporate strategy.

Fourth quarter Group revenue grew at 48% year-to-year to US$15.6 billion. Profit recorded its highest growth rate in two years – with pre-tax income of US$380 million and net income of US$260 million – up 392% and 512% respectively. The Q4 results closed out a record year, with annual Group revenue surging past US$60 billion, adding more than US$10 billion on the previous fiscal year. Profit grew even faster, with pre-tax income of almost US$1.8 billion and net income of US$1.2 billion – both up more than 70% year-on-year.

Lenovo’s Board of Directors declared a final dividend of 3.09 US cents or 24 HK cents per share for the fiscal year ended March 31, 2021.

Financial Highlights:

 

FY 20/21
US$ millions

FY 19/20
US$ millions

Change

 

Q4 20/21
US$ millions

Q4 19/20
US$ millions

Change

Group Revenue

60,742

50,716

20%

15,630

10,579

48%

Pre-tax income

1,774

1,018

74%

380

77

392%

Net Income

(profit attributable to equity holders)

1,178

665

77%

260

43

512%

 

 

Basic earnings per share (US cents)

9.54

5.58

3.96

2.19

0.36

1.83

Chairman and CEO quote – Yuanqing Yang:

“Last quarter, we delivered our fastest growing quarter in almost a decade and closed the fiscal year with the new milestone of passing US$60 billion in revenue and significant growth in profit to a new record. These historic highs were achieved by leveraging our core competencies of a clear strategy, innovative products, operational excellence, and global-local model to meet the new needs in the New Normal.” said Yuanqing Yang, Lenovo Chairman and CEO. “Looking forward, we will capture the huge growth opportunities created by the market trends of information consumption upgrade, infrastructure upgrade and application upgrade to drive long-term sustainable growth and ensure we can build an even smarter future in the years ahead.”

Fourth quarter record driven by simultaneous double-digit revenue growth across all core businesses

  • Best fourth quarter ever for PC and Smart Devices (PCSD) with US$12.4 billion in revenue, up 46% year-on-year and profitability at an all-time high of 6.7%.
  • All geographies realized high double-digit growth in PCSD revenue and PC volume outgrew the market – further strengthening the company’s global #1 ranking in PCs.
  • Tablets had a breakthrough quarter, with shipments growing 157% year-on-year – around three times as fast as the market.
  • High growth and premium segment volumes (Gaming, Thin & Light, Chromebooks, Visuals) continue to outgrow the market and deliver strong double to triple-digit growth rates.
  • Revenue from the Mobile Business Group (MBG) achieved hyper-growth, up 86% year-on-year to US$1.54 billion – achieving pre-tax income of US$21 million – a record high since the Motorola acquisition.
  • Expanded carrier relationships and a strong product portfolio, including 5G products, saw smartphone volumes grow at triple digit rate in North America, Europe, and Asia Pacific.
  • Smartphone market share in our Latin America stronghold reached a record of nearly 21%.
  • Revenue for the Data Center Group (DCG) was strong, growing 32% year-on-year to US$1.6 billion, the fifth straight quarter of premium-to-market growth. Profitability improved 4.4 points year-on-year.
  • The Cloud Service Provider business grew 73% year-on-year and at a 61-point premium to the market.
  • Record high fourth quarter revenue was achieved for Server, Storage, Software Defined Infrastructure, Software, and HPC/AI. Traditional storage was a particular highlight growing at 73% year-on-year.
  • Burgeoning Edge business delivering strong signs of future growth.
  • Transformation businesses also achieved record growth, fueled by ongoing strong growth in services and software revenue* up 44% year-on-year. Managed Services revenue* (DaaS, TruScale) nearly doubled, and Solutions revenue* grew 65% year-on-year.

Fiscal year milestone fueled by leveraging core competencies of clear strategy, product innovation, operational excellence, and Global/Local model

  • For the first time, Group revenue surged past US$60 billion, adding more than US$10 billion, or 20% year-on-year growth in just one year.
  • Intelligent Devices Group (PCSD and MBG) and Data Center Group achieved revenue growth of 20% and 15% respectively.
  • The Group’s Service-led transformation is forging ahead. Software and Services revenue grew twice as fast at the overall Group revenue, at almost 40% year-on-year to a record US$4.9 billion – now makes up 8%* of Group revenue.

Operational highlights

  • Effective April 1, 2021, the Lenovo Group brought together services and solutions teams and capabilities from across the company to form a dedicated organization - the new Solutions & Services Group (SSG). This business group will further strengthen our attached services portfolio and increase attach rates, enhance and expand managed services, and develop repeatable solutions in key vertical industries.
  • The Group’s global supply chain continues to be best-in-class with the global footprint expanding to include a new in-house factory in Hungary which will be fully operational later in 2021. Most recently Gartner ranked Lenovo as one of the world’s top 25 supply chains, citing the company as a stand-out performer in customer-driven business transformation, noted for embracing the use of advanced technologies like 5G, blockchain and artificial intelligence to optimize the delivery of products and solutions to customers across 180 markets.
  • Progress and ambitions around sustainability continue at a significant pace, with Scope 1 and 2 greenhouse gas emissions reduced by 92% over the past decade and have new aggressive science-based targets for 2030 in place to drive progress even harder. The company has also been recognized by the annual Corporate Knights Index as one of the world’s 100 most sustainable companies.
  • The company was named as one of the world’s most innovative companies by Boston Consulting Group – ranking 25 out of the top 50.

Business outlook

The challenges of FY 20/21 continue, in varying degrees, into the new year. Nevertheless, with the permanent market changes accelerated over the past year the Group’s outlook for the rest of 2021 and the 21/22 fiscal year remains positive. The market changes over the past year are fueling three major trends that the Group is capitalizing on. Firstly, the consumption upgrade, with customers spending more time on their devices, buying more, and upgrading more often. Secondly, the infrastructure upgrade, with customers moving from buying data center products to buying total infrastructure solutions. And finally, the application upgrade, with digitalization greatly accelerated and intelligent transformation, enabled by A.I., becoming a reality. Lenovo’s proven track record for execution, its global-local operating model, and new organizational structure aligns to these trends, will further strengthen the Group’s ability to drive long-term, sustainable growth.

* invoiced revenue

About Lenovo

Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub.

 

LENOVO GROUP

FINANCIAL SUMMARY

For the fiscal quarter and full year ended March 31, 2021

(in US$ millions, except per share data)

 

 

 

Q4
FY20/21

Q4
FY19/20

 

Y/Y CHG

 

 

FY20/21

 

FY19/20

 

Y/Y CHG

Revenue

 

15,630

10,579

48%

 

60,742

50,716

20%

Gross profit

 

2,688

1,861

44%

 

9,768

8,357

17%

Gross profit margin

 

17.2%

17.6%

(0.4)pts

 

16.1%

16.5%

(0.4)pts

Operating expenses

 

(2,209)

(1,695)

30%

 

(7,588)

(6,918)

10%

Expenses-to-revenue ratio

 

14.1%

16.0%

(1.9)pts

 

12.5%

13.6%

(1.1)pts

Operating profit

 

479

166

188%

 

2,180

1,439

52%

Other non-operating expenses - net

 

(99)

(89)

11%

 

(406)

(421)

(3)%

Pre-tax income

 

380

77

392%

 

1,774

1,018

74%

Taxation

 

(95)

(14)

585%

 

(461)

(213)

116%

Profit for the period/year

 

285

63

350%

 

1,313

805

63%

Non-controlling interests

 

(25)

(20)

20%

 

(135)

(140)

(3)%

Profit attributable to equity holders

 


260

43


512%

 


1,178


665


77%

Earnings per share (US cents)

 

 

 

 

 

 

 

 

Basic

2.19

0.36

1.83

9.54

5.58

3.96

Diluted

1.94

0.35

1.59

8.91

5.43

3.48

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Hong Kong – Angela Lee, angelalee@lenovo.com, +852 2516 4810
London – Charlotte West, cwest@lenovo.com, +44 7825 605720
Zeno Group - LenovoWWcorp@zenogroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Celltrion Healthcare presents the first real-world data for Truxima® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 18:45:00 EEST | Press release

Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t

 Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 10:01:00 EEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),

New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 10:00:00 EEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 12:53:00 EEST | Press release

Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As

Slots Capital on useampien pelaajien ulottuvilla kuin koskaan aiemmin11.6.2021 12:23:00 EEST | Tiedote

Slots Capital on yksi maailman suosituimmista nettikasinoista. Nyt se on useampien pelaajien ulottuvilla kuin koskaan aiemmin, kun sivusto on ensimmäistä kertaa käynnistänyt toimintansa useissa uusissa maissa. Tämä tarkoittaa, että pelaajat Belgiassa, Romaniassa, Kreikassa, Tanskassa, Suomessa, Irlannissa, Latviassa ja Luxemburgissa voivat nyt nauttia Slots Capitalin huippuluokan nettikasinokokemuksesta. Jos rakastat kolikkopelien pelaamista, Slots Capital on todellakin sinua varten tarjoten yli 300 peliä isoilta pelinkehittäjiltä, kuten Rival, Saucify, Dragon ja Qora. Itse asiassa lisäsimme hiljattain kolikko- ja pöytäpeliaulaamme pelejä suosituilta studioilta, kuten Rival Gamingilta, Dragon Gamingilta, Saucify Gamingilta ja Qora Gamingilta. Lisäämme pelejä myös Arrow's Edgelta tulevina viikkoina, mutta sillä välin pelaajat voivat kokeilla peliaulamme uusimpia pelejä kuten: Dead Beats Irish Wishes Lucky Macau Panda Playtime Sands of Space Twin Dragons Viking Victory Win Another Day Wr

Slots Capital Available to More Players Than Ever Before11.6.2021 12:21:00 EEST | Press release

Slots Capital, one of the most popular online casinos in the world, in now available to more players than ever before after launching into several new countries for the very first time. This means players in Belgium, Romania, Greece, Denmark, Finland, Ireland, Latvia and Luxembourg can now enjoy the top-rated online casino experience offered at Slots Capital. If you love playing slots, then Slots Capital really is the place to be. In fact, we recently boosted our slots and table games lobby with titles from in-demand studios including Rival Gaming, Dragon Gaming, Saucify Gaming and Qora Gaming. We will also be adding slots from Arrow’s Edge in the coming weeks but in the meantime, players can try the latest titles to hit our lobby including: Dead Beats Irish Wishes Lucky Macau Panda Playtime Sands of Space Twin Dragons Viking Victory Win Another Day Wrath of Medusa Yeti Hunt i3D Slots Capital is not only known for being the number one destination for slots, players also love our daily

Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 11:15:00 EEST | Press release

The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom